# Antengene Corporation Limited

Type: Company (6855.HK)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/antengene-corporation-limited
Canonical HTML page: https://getbiobrief.com/entity/antengene-corporation-limited

## Timeline

- **2026-03-04**: Investor Briefings — Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
- **2026-03-03**: Global License Agreement — Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
- **2026-Q1**: Regulatory Filings — Planned submission of clinical trial applications for ATG-201 in China and Australia.

## Recent coverage (2 stories)

### Antengene Debuts TriGager TCE and ATG-207 at 2nd Biotech Summit
2026-08-23 20:02:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Full story: https://getbiobrief.com/story/antengene-trigager-tce-atg207-biotech-summit

### UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot
2026-03-04 00:38:57 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
Full story: https://getbiobrief.com/story/ucb-antengene-atg201-licensing-deal-autoimmune

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.